Skip to content
OpenCapital
Get started

BioXcel Therapeutics, Inc. BTAI Q4 2024 Annual earnings

Reported March 27, 2025 · Before market open

Revenue$366.0KMiss by $352.3K
EPS-$3.57Beat by $0.79
Revenue estimate$718.3K
EPS estimate-$4.36

Next report

Aug 11, 2026 (In 1 week)
Revenue estimate$423.1K
EPS estimate-$0.42

Versus estimates

Revenue

Q1 2026$206.0KMiss by $175.5KQ4 2025$256.0KBeat by $104.5KQ3 2025$98.0KMiss by $71.0KQ2 2025$120.0KMiss by $137.5KQ1 2025$168.0KMiss by $182.0K
Q4 2024$366.0KMiss by $352.3K

Diluted EPS

Q1 2026-$0.54Miss by $0.01Q4 2025-$0.58Miss by $0.24Q3 2025-$2.18Miss by $0.64Q2 2025-$2.45Miss by $0.15Q1 2025-$1.50Beat by $1.22
Q4 2024-$3.57Beat by $0.79

Ask the moment BioXcel Therapeutics, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did BioXcel Therapeutics, Inc. report Q4 2024 earnings?
BioXcel Therapeutics, Inc. (BTAI) reported Q4 2024 earnings on March 27, 2025 before market open.
What were BioXcel Therapeutics, Inc.'s Q4 2024 revenue and EPS?
BioXcel Therapeutics, Inc. reported revenue of $366.0K and eps of $-3.57 for Q4 2024.
Did BioXcel Therapeutics, Inc. beat estimates in Q4 2024?
Revenue missed the consensus estimate of $718.3K by $352.3K. EPS beat the consensus estimate of $-4.36 by $0.79.
Where can I find BioXcel Therapeutics, Inc.'s Q4 2024 SEC filings?
You can read the 10-K periodic report (0001558370-25-003985) directly on SEC EDGAR. The filing index links above go to sec.gov.